Reneo Pharmaceuticals, Inc. announced that it expects to receive $65 million in funding from OnKure, Inc., RADIATE MERGER SUB II, LLC, Radiate Merger Sub I, Inc

Reneo Pharmaceuticals, Inc entered into a Subscription Agreement of common shares for a gross proceeds $65,000,000 on May 10, 2024.The transaction includes participation from OnKure, Inc, RADIATE MERGER SUB II, LLC and Radiate Merger Sub I, Inc.